Is the vial impacting your results?
Poster-Vendor
Poster Presentation
Presented by A. Harder
Prepared by
Contact Information: craig_douglas@agilent.com; 800-277-9770
ABSTRACT
With instrument detection limits pushing ever lower, Agilent strives to control the impact of all consumables within the analytical system. Often the vial is an overlooked component of this system, where even minor interactions could impact the quality and reliability of the analytical results. This is of particular importance when analyzing long sequences where prepared samples may be stored for periods of time before analysis, and hence where consistency of results over time is essential.
Variations in the glass surface can translate into variability in your analytical results, in ways that we cannot fully predict. It therefore makes sense that consistency of the manufacturing process would translate into consistency of your analytical results. Agilent is pleased to introduce a new range of vials which utilizes proprietary manufacturing steps, designed to reduce variability in order to limit the impact of the vial on your analysis.
The tricyclic antidepressant Doxepin was used as a model compound to illustrate the non-specific interaction of analytes at low concentrations with the interior surface of a vial. Doxepin recoveries were monitored over time using LC/MS/MS.
Poster-Vendor
Poster Presentation
Presented by A. Harder
Prepared by
Contact Information: craig_douglas@agilent.com; 800-277-9770
ABSTRACT
With instrument detection limits pushing ever lower, Agilent strives to control the impact of all consumables within the analytical system. Often the vial is an overlooked component of this system, where even minor interactions could impact the quality and reliability of the analytical results. This is of particular importance when analyzing long sequences where prepared samples may be stored for periods of time before analysis, and hence where consistency of results over time is essential.
Variations in the glass surface can translate into variability in your analytical results, in ways that we cannot fully predict. It therefore makes sense that consistency of the manufacturing process would translate into consistency of your analytical results. Agilent is pleased to introduce a new range of vials which utilizes proprietary manufacturing steps, designed to reduce variability in order to limit the impact of the vial on your analysis.
The tricyclic antidepressant Doxepin was used as a model compound to illustrate the non-specific interaction of analytes at low concentrations with the interior surface of a vial. Doxepin recoveries were monitored over time using LC/MS/MS.
